Treatment News : Dolutegravir Regimen Bests Atripla as First-Line HIV Therapy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 17, 2012

Dolutegravir Regimen Bests Atripla as First-Line HIV Therapy

Dolutegravir, an experimental once-daily integrase inhibitor being developed by ViiV Healthcare and Shionogi, combined with Epzicom (abacavir plus lamivudine), appears to have an efficacy advantage over Atripla (efavirenz plus tenofovir and emtricitabine) among people starting HIV treatment for the first time. According to data from the 830-person Phase III SINGLE clinical trial presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, 88 percent of volunteers using dolutegravir and Epzicom, compared with 81 percent of those using Atripla, had undetectable viral loads after 48 weeks of treatment—a statistically significant difference—though this was primarily driven by a higher rate of discontinuations in the Atripla group because of side effects. Whereas those in the Atripla group were more likely to experience central nervous system-related side effects, insomnia was more common among those in the dolutegravir group. A one-daily single table combining dolutegravir, abacavir and lamivudine, currently dubbed 572-Trii, is in development.

To review the 52nd ICAAC abstract, click here.

Search: dolutegravir, integrase inhibitor, viiv, shionogi, epzicom, abacavir, lamivudine, atripla, treatment naive, efficacy, phase iii, , single, icaac


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    Sin_Grinder
    Reno
    Nevada


    youngbloodlatino
    Columbia
    Maryland


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.